SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Down 5% – Here’s Why

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) traded down 5% during trading on Friday . The stock traded as low as $8.45 and last traded at $8.47. Approximately 32,677 shares changed hands during trading, a decline of 87% from the average session volume of 242,677 shares. The stock had previously closed at $8.92.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research increased their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Trading Down 9.3%

The stock has a market cap of $678.71 million, a price-to-earnings ratio of -7.03 and a beta of 0.96. The business’s 50 day moving average is $6.46 and its 200 day moving average is $5.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the sale, the chief executive officer owned 670,651 shares of the company’s stock, valued at approximately $3,500,798.22. This trade represents a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 17,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the sale, the insider owned 590,887 shares in the company, valued at $4,307,566.23. The trade was a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 334,842 shares of company stock worth $2,110,215. 4.88% of the stock is owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently bought and sold shares of the company. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the second quarter worth about $9,809,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at approximately $567,000. Royal Bank of Canada increased its position in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.